pharmaceutical investing Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update
Independent CTRI Testing Indicates RZOLV Exhibits Dramatically Lower Acute Trout Toxicity Than Cyanide Reference
FPX Nickel and JOGMEC Delineate Multiple Awaruite Nickel Targets at the Expanded Klow Property in British Columbia
